Release date: 2018-07-06
This article takes stock of the latest clinical development pipeline for Alzheimer's disease in June 2018. We collected clinical trial data on clinical Alzheimer's disease in Phase 1, Phase 2, and Phase 3, registered at clinicaltrials.gov. Included in the statistics are trials that are being recruited, recruited, and issued recruitment notices, and do not include trials that have been completed, terminated, unknown, withdrawn, and suspended.
Progress in clinical research and development of new drugs for Alzheimer's disease
As of June 31, 2018, there were 201 clinical trials of new drugs in the field of Alzheimer's disease, and Phase 2 trials dominated. The 201 studies included 54 trials in Phase 1, including 46 small molecule drugs and 8 biopharmaceuticals; 108 trials in Phase 2, including 101 small molecule drugs and 7 biological drugs; There are 39 trials, including 39 small molecule drugs and 0 biological drugs (note: some drugs may be tested simultaneously).
The clinical trials of new drugs for Alzheimer's disease are concentrated in the United States. According to the location of the research institutions of clinical trials, the top 5 countries or regions are: 139 trials in the United States, 36 in Canada, 31 in the United Kingdom, and 29 in Spain. 27 Australia (Note: There may be a multi-center clinical trial).
The world's leading companies investigating new drugs for Alzheimer's disease are:
Eli Lilly and Company (10 items), Hoffmann-La Roche (7 items), Biogen (5 items), Avid Radiopharmaceuticals (5 items), Cognition Therapeutics (4 items), Avanir Pharmaceuticals (4 items), Genentech, Inc. ( 4 items), Janssen Research & Development, LLC (4 items), Corium International Inc. (4 items), Navida Biopharmaceuticals (3 items), Eisai Inc. (3 items), VA Office of Research and Development (3 items), William Charles Kreisl (3 items), United Neuroscience Ltd. (2 items), Neurotrope Bioscience, Inc. (2 items), Medipost Co Ltd. (2 items), Eisai Co., Ltd. (2 items), Sunnybrook Health Sciences Centre (2 items), Novartis Pharmaceuticals (2 items), Charsire Biotechnology Corp. (2 items).
New clinical trial of new Alzheimer's disease in June
In June 2018, four new clinical trials of Alzheimer's disease were added. On average, 17 subjects were recruited in 2 Phase 1 trials, 100 subjects were recruited on average in 1 Phase 2 trial, and 225 subjects were recruited on average in 1 Phase 3 trial.
We expect these clinical trials to go well and achieve positive results as soon as possible, bringing hope for treatment to patients.
Original title: Inventory | What are the latest clinical development pipelines for Alzheimer's disease?
Source: WuXi PharmaTech
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com